Want to see IN:IOLCP full AI Analyst Report?
IOLCP Stock Chart & Stats
₹84.09
-₹4.90(-1.13%)
At close: 4:00 PM EST
₹84.09
-₹4.90(-1.13%)
Day’s Range― - ―
52-Week Range₹67.14 - ₹219.05
Previous CloseN/A
Volume410.76K
Average Volume (3M)311.88K
Market Cap
₹56.80B
Enterprise Value₹20.69K
Total Cash (Recent Filing)₹2.00B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)31.4
Beta1.56
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)5.72
Shares Outstanding293,527,500
10 Day Avg. Volume378,892
30 Day Avg. Volume311,876
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.19
Price to Sales (P/S)0.92
P/FCF Ratio55.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.1
Revenue Forecast (FY)₹25.66B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and sustained equity growth provide financial resilience, reduce dependence on external funding, and give IOLCP flexibility to manage chemical cycles, fund compliance needs, and invest through weaker operating periods.
Diversified Manufacturing BaseExposure to both APIs and chemicals diversifies demand sources and can reduce reliance on one product market. Established manufacturing across these categories also supports customer reach and operating continuity over the medium term.
Recent Earnings RecoveryThe reported recovery in revenue and earnings indicates improved recent operating momentum after weaker periods. If supported by volumes, mix, and disciplined costs, it could strengthen internal funding and improve returns over the next several quarters.
Bears Say
Material Margin CompressionThe sharp decline in gross and net margins shows that prior earnings strength has not been sustained. Weaker pricing or product mix, alongside higher costs, could continue limiting profit growth even if revenue improves.
Weak Free Cash Flow ConversionIrregular free cash flow and low conversion of profit into surplus cash reduce earnings quality and financial flexibility. Continued investment or working-capital needs could constrain dividends, deleveraging, or capacity expansion.
Uneven Revenue TrajectoryThe multi-year revenue pattern points to inconsistent demand or pricing across APIs and chemicals rather than dependable expansion. This makes utilization, product mix, and industry-cycle management important to sustaining future growth.
IOL Chemicals & Pharmaceuticals Ltd. News
IOLCP FAQ
What was IOL Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
IOL Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹67.14 and its highest was ₹219.05 in the past 12 months.
What is IOL Chemicals & Pharmaceuticals Ltd.’s market cap?
IOL Chemicals & Pharmaceuticals Ltd.’s market cap is ₹56.80B.
When is IOL Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
IOL Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 63 days.
How were IOL Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
IOL Chemicals & Pharmaceuticals Ltd. released its earnings results on Aug 10, 2026. The company reported ₹2.2 earnings per share for the quarter.
Is IOL Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts IOL Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does IOL Chemicals & Pharmaceuticals Ltd. pay dividends?
IOL Chemicals & Pharmaceuticals Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.56%. See more information on IOL Chemicals & Pharmaceuticals Ltd. dividends here
What is IOL Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
IOL Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IOL Chemicals & Pharmaceuticals Ltd. have?
IOL Chemicals & Pharmaceuticals Ltd. has 293,527,500 shares outstanding.
What happened to IOL Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
IOL Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹2.2 in its last earnings report. Following the earnings report the stock price went down -1.698%.
Which hedge fund is a major shareholder of IOL Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:IOLCP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IOL Chemicals & Pharmaceuticals Ltd.
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide array of active pharmaceutical ingredients (APIs), featuring prominent pain and fever relievers such as ibuprofen, ibuprofen lysinate, ibuprofen sodium, and dex-ibuprofen. The company also provides other crucial APIs, including metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, and fenofibrate. These compounds are integral to treatments addressing various conditions, such as inflammation, pain relief, fever reduction, diabetes, platelet aggregation, cholesterol management, seizures, gallstones, and gastric acid inhibition. In addition to pharmaceuticals, IOL supplies specialized industrial chemicals like ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid. These chemicals are widely utilized across numerous industries, including food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and as chemical intermediates.
Technical Analysis
Aarti Drugs Limited
―
Granules India Limited
―
Hikal Limited
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―